Accelerate Diagnostics (AXDX) Stock Price, News & Analysis

Company Overview

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.03 to $1.18
• 52-Week Range: N/A
• Volume: 53.64 million shs
• Average Volume: 521,768 shs
• Market Capitalization: $857 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

AXDX Stock Analysis - Frequently Asked Questions

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) issued its earnings results on Thursday, March, 20th. The medical research company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.13. The medical research company had revenue of $2.82 million for the quarter, compared to analyst estimates of $3 million.

When did Accelerate Diagnostics' stock split?

Shares of Accelerate Diagnostics reverse split on the morning of Wednesday, July 12th 2023.The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' top institutional investors include Griffin Asset Management Inc. (3.38%) and Simplex Trading LLC. Insiders that own company stock include Jack Phillips, Larry Michael Mertz, David Patience and Steven Reichling.
View institutional ownership trends.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Accelerate Diagnostics investors own include Himax Technologies (HIMX), Sangamo Therapeutics (SGMO), Magnachip Semiconductor (MX), Universal Display (OLED), Energy Transfer (ET), Fluidigm (FLDM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 3/20/2025
• Today: 6/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:AXDX
• CIK: 727207
• Web: acceleratediagnostics.com
• Phone: (520) 365-3100
• Fax: 520-269-6580
• Employees: 220
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.62 million
• Net Margins: -471.83%
• Pretax Margin: -444.14%
• Return on Equity: N/A
• Return on Assets: -191.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.50
• Quick Ratio: 1.34

Sales & Book Value

• Annual Sales: $11.70 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.37) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 25,210,000
• Free Float: 14,125,000
• Market Cap: $857 thousand
• Optionable: Optionable
• Beta: 0.22